The use of a clinical practice guideline to manage and verify the weight loss outcomes of patients treated with fen-phen in primary care settings

Nutrition in Clinical Practice

Volumn 13, Issue 5, 1998, Pages 241-250

  Pitts, Bruce G ^a   Crosby, Ross ^b   Laufenberg, Susan ^a   Meidinger, Gail ^a   Monson, Nancy ^b  

^a Meritcare Health System   (United States)

^b NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 55449095286     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/088453369801300508     Document Type: Article

References (11)

1. HHS News, US Department of Health and Human Services. September 15, 1997:P97.32.
2. Langreth R. Critics claim diet clinics misuse obesity drugs. Wall Street Journal. March 31, 1997: B8.
3. Hitzig@fenphen.com.
4. Connelly HM, Crary JL, McGood MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
5. Kassirir JP, Angell M. Prepublication Release of Journal Articles. N Engl J Med 1997;337:1762-3.
6. www.fda.gov/cder/news/feninfo.htm: FDA analysis of cardiac valvular dysfunction in patients treated with appetite suppressants. September 1997:17.
7. Weintraub M, Hadsay JD, Mushlin AI, et al. A double-blind clinical trial in weight loss control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984; 144:1143-8.
8. Weintraub M. Long-term weight loss control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51:581-646.
9. Deitch MW. Wyeth-Ayerst Laboratories. December 1996.
10. Deitch MW. Wyeth-Ayerst Laboratories. January 1997.
11. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993;50:739-50.